José Manasanch Dalmau (J Manasanch, José Manasanch)
Publication Activity (10 Years)
Years Active: 2018-2022
Publications (10 Years): 5
Publications (10 Years): 5
Publications
- Antonio Alcaraz, David M Castro-Díaz, Mauro Gacci, Alessia d'Arma, Vincenzo Ficarra, Joaquín Carballido-Rodríguez, Alfredo Rodríguez-Antolín, Jose Medina-Polo, Jesús María Fernández-Gómez, José M Cózar-Olmo, Santiago Búcar-Terrades, Noemí Pérez-León, Francisco J Brenes-Bermúdez, José M Molero, Antonio Fernández-Pro-Ledesma, Michael Herdman, Javier C Angulo, José Manasanch Dalmau, null On Behalf Of The Qualiprost Study Group
- Antonio Alcaraz, Mauro Gacci, Vincenzo Ficarra, Jose Medina-Polo, Andrea Salonia, Jesús M Fernández-Gómez, Alexandru Ciudin, David Castro-Díaz, Alfredo Rodríguez-Antolín, Joaquín Carballido-Rodríguez, José M Cózar-Olmo, Santiago Búcar-Terrades, Noemí Pérez-León, Francisco J Brenes-Bermúdez, José M Molero-García, Antonio Fernández-Pro Ledesma, Michael Herdman, José Manasanch Dalmau, Javier C Angulo, On Behalf Of The Qualiprost Study Group
- Antonio Alcaraz, Alfredo Rodríguez-Antolín, Joaquín Carballido-Rodríguez, David Castro-Díaz, Manuel Esteban-Fuertes, José M Cózar-Olmo, Vincenzo Ficarra, Rafael Antonio Medina-López, Jesús M Fernández-Gómez, Javier C Angulo, Jose Medina-Polo, Francisco J Brenes-Bermúdez, José M Molero-García, Antonio Fernández-Pro-Ledesma, José Manasanch Dalmau, On Behalf Of The Qualiprost Study Group
- Camil Castelo-Branco, M J Cancelo Hidalgo, Santiago Palacios, M Ciria-Recasens, A Fernández-Pareja, Cristina Carbonell-Abella, José Manasanch Dalmau, J Haya-Palazuelos
- Remigio Vela-Navarrete, Antonio Alcaraz, Alfredo Rodríguez-Antolín, Bernardino Miñana López, Jesús M Fernández-Gómez, Javier C Angulo, David Castro Díaz, Javier Romero-Otero, Francisco J Brenes, Joaquín Carballido, José Mª Molero García, Antonio Fernández-Pro Ledesma, José Manuel Cózar Olmos, José Manasanch Dalmau, Isaac Subirana Cachinero, Michael Herdman, Vincenzo FicarraEfficacy and safety of a hexanic extract of Serenoa repens (Permixon® ) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic review and meta-analysis of randomised controlled trials and observational studies. BJU international 122 (6) (2018)